In a major move to bolster its international presence, pharmaceutical giant Lupin Limited has announced a significant licensing and supply agreement with Galenicum Health, S.L.U..
The partnership, facilitated through Lupin’s subsidiary Lupin Atlantis Holdings SA (LAHSA), focuses on the finished formulations of injectable Semaglutide, a potent GLP-1 receptor agonist.
The agreement marks a strategic milestone for Lupin as it seeks to address the escalating global challenges of Type 2 Diabetes and obesity.
Under the terms of the deal, Galenicum will oversee the development, manufacturing, and supply of the product, while Lupin will be responsible for regulatory submissions, approvals, and commercial distribution.
The rollout is set to span 23 countries, including key markets in Canada, Europe, Southeast Asia, and Latin America.
The demand for Semaglutide has surged globally due to its efficacy in regulating blood sugar and appetite. Fabrice Egros, President of Corporate Development at Lupin, emphasised that this collaboration allows the company to “scale access at the right moment,” further reinforcing Lupin’s commitment to high-quality, cost-effective medicines.
Galenicum, headquartered in Barcelona, has invested heavily in its GLP-1 development pipeline to meet this rising demand.
Joaquim Domingo, co-founder of Galenicum, stated that the partnership is a cornerstone of their strategy to become a leader in the B2B GLP-1 space.
With 15 manufacturing sites and 7 research centres globally, Lupin is already a established leader in respiratory, cardiovascular, and anti-diabetic therapies.
This new venture into the Semaglutide market is expected to expand Lupin’s leadership in diabetes care and obesity beyond its strong home base in India.
As the GLP-1 market continues to expand, this partnership positions both companies to transform patient care by providing reliable and affordable therapeutic options on a global scale.
Document signed by: Amit Kumar Gupta, Company Secretary & Compliance Officer of Lupin Limited. Source of Information: Official Press Release and Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
